The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2006Engrailed as a Potential Therapeutic Target in Parkinson's Disease
Parkinson’s disease is associated with the preferential loss of a population of dopaminergic neurons in the substantia nigra, a specific structure of the midbrain. It was shown very recently that...
-
Community Fast Track, 2006Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being...
-
Community Fast Track, 2006CDNF a novel conserved neurotrophic factor that protects midbrain dopaminergic neurons in vivo
Neuroprotective or neurorestorative therapies for Parkinson's disease are still evolving. We have identified a novel conserved dopamine neurotrophic factor (CDNF) protein which might be beneficial for...
-
Community Fast Track, 2006Specific Intracellular Targeting of Oligomeric Alpha-synuclein as a Potential Therapeutic for Parkinson's Disease
The protein alpha-synuclein is a major constituent of the Lewy Body aggregates that are a hallmark feature of Parkinson's disease. Several genetic studies have also correlated aggregation of alpha...
-
Community Fast Track, 2006Roles of Parkin/PINK1/DJ-1 Complex in Parkinson's Disease Pathogenesis
Mutations in at least six genes, including alpha-synuclein, uchL1, LRRK2, parkin, PINK1, and DJ-1, are linked to Parkinson's disease. One vital question is how mutations in six different genes...
-
Therapeutics Development Initiative, 2006Small molecule TNF-alpha inhibitors as neuroprotectant drugs for PD
Several preclinical and clinical studies implicate the neuroinflammatory cytokine TNF-alpha as a key mediator in PD-associated neurodegenerative pathology. P2D, Inc. has recently identified four lead...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.